马来西亚批准针对某些淋巴瘤病人的XPOVIO,扩大在本区域的使用范围。 Malaysia approves XPOVIO for certain lymphoma patients, expanding its use in the region.

马来西亚已经批准XPOVIO(selinexor),治疗重症复发或易碎性扩散的大型B细胞淋巴瘤成年病人,这些病人至少曾接受过两次治疗,并且没有资格接受干细胞移植。 Malaysia has approved XPOVIO (selinexor) for adult patients with relapsed or refractory diffuse large B-cell lymphoma who have had at least two prior treatments and are ineligible for stem cell transplant. 这使得该药在马来西亚的使用范围扩大到三种适用症,其中包括两种用于多发性骨髓瘤. This expands the drug’s use in Malaysia to three indications, including two for multiple myeloma. XPOVIO是第一个口服选择性XPO1抑制剂,现已在10个亚太市场获得批准,并列入5个国家的国家保险,如中国、新加坡和韩国。 XPOVIO, the first oral selective XPO1 inhibitor, is now approved in ten Asia-Pacific markets and included in national insurance in five, such as China, Singapore, and South Korea. 批准为选择有限替代品的病人提供了新的治疗办法。 The approval offers new treatment options for patients with limited alternatives. 该药物背后的生物技术公司Antengene在美国和亚洲拥有32份IND批准书,并在11个亚太市场上提交了NDA。 Antengene, the biotech company behind the drug, has 32 IND approvals in the U.S. and Asia and submitted NDAs in 11 Asia-Pacific markets.